特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の乗り物酔い薬市場:成長、動向、および予測

Motion Sickness Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 922022
出版日 ページ情報 英文 115 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
世界の乗り物酔い薬市場:成長、動向、および予測 Motion Sickness Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日: 2020年06月01日 ページ情報: 英文 115 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートは世界の乗り物酔い薬市場について調査しており、市場機会や動向、成長および阻害要因、治療タイプ・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 世界の旅行者数と仮想現実の利用の増加
    • 乗り物酔い薬の採用増加
  • 市場の阻害要因
    • 処方薬の高いコストによる新興国の難色
    • OTCと伝統薬への過度の依存
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 治療タイプ別
    • 抗コリン薬
    • 抗ヒスタミン薬
    • その他
  • 流通チャネル別
    • 小売薬局
    • オンライン薬局
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • GlaxoSmithKline plc
    • Perrigo Company plc
    • Prestige Brands Inc
    • WellSpring Pharmaceutical Corporation
    • Caleb Pharmaceuticals Inc
    • Myungmoon Pharm Co. Ltd
    • Baxter International Inc
    • Reliefband Technologies LLC
    • CVS Health

第7章 市場機会および今後の動向

目次
Product Code: 67651

The motion sickness treatment market is anticipated to witness a CAGR of nearly 3.0% during the forecast period. There are certain factors that are driving the market growth, including a rise in the number of travelers across the globe and increased incidences of cardiovascular diseases in the geriatric population which majorly cause motion sickness.

For instance, according to United Nations World Tourism Organization (UNWTO), international tourist arrivals increased by 5.4% in 2018 compared to 2017, and this tendency is expected to continue throughout the forecast period which demands higher requirements for motion sickness treatment globally. Also, ongoing research activities in motion sickness drug development and delivery systems are likely to increase the availability of OTC drugs for motion sickness treatment.

Key Market Trends

Anticholinergic Treatment Segment is Expected to Hold the Largest Market Share During the Forecast Period

The anticholinergic treatment segment is expected to account for a significant share of the motion sickness treatment market. The dominance in the revenue share of this segment is due to long-lasting relief, better efficacy, better patient-compliance, and fewer side effects compared to other treatments. Also, the growing demand along with the higher prices of these products is expected to contribute to the highest revenue of the segment during the forecast period.

Next to anticholinergics, the antihistamine treatment segment contributes to the second-highest revenue in the global market. This is due to their access to the patients in a wide range of dosage forms like transdermal patches, oral dosage forms such as chewable tablets, lozenges, etc., as per patient requirement. They are also available as prescriptions and various OTC drugs which are expected to account for their significant growth rate in the motion sickness treatment market.

By the distribution channel, the retail pharmacies segment is expected to have a high revenue share in the market and is expected to continue during the forecast period. The dominance is owing to the higher preference of self-medication and the access to patients which accounts for the significant share in the market.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to account for the largest share of the motion sickness treatment. This is due to increased tourism in the U.S. and preference for highly expensive prescription drugs directly contributes to a significant share of revenue in the region. For instance, according to the UNWTO, in 2018, nearly 52 million International tourists travel from America to Europe resultant in a higher demand for the motion sickness treatment market in the region.

Followed by North America, Europe contributed to the second largest market share owing to a rise in a number of travelers all over the world, increased research activities and investors to develop novel drug delivery systems for motion sickness treatment accounts for the highest revenue.

Competitive Landscape

The motion sickness treatment market is moderately competitive and consists of several major players. Few of the major players currently dominating the market are implementing various development strategies such as making mergers and acquisitions, entering into partnerships and thus, expanding their footprint globally.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Number of Travellers and Virtual Reality Exposure Across the Globe
    • 4.2.2 Rise in Adoption of Prescription Motion Sickness Drugs
  • 4.3 Market Restraints
    • 4.3.1 Reluctance in Emerging Countries due to Higher Cost of Prescription Drugs
    • 4.3.2 Excessive Reliance on the OTC and Traditional Medicines
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 Anticholinergics
    • 5.1.2 Antihistamines
    • 5.1.3 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Retail Pharmacies
    • 5.2.2 Online Pharmacies
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GlaxoSmithKline plc
    • 6.1.2 Perrigo Company plc
    • 6.1.3 Prestige Consumer Healthcare Inc.
    • 6.1.4 WellSpring Pharmaceutical Corporation
    • 6.1.5 Caleb Pharmaceuticals Inc
    • 6.1.6 Myungmoon Pharm Co. Ltd
    • 6.1.7 Baxter International Inc
    • 6.1.8 CVS Health

7 MARKET OPPORTUNITIES AND FUTURE TRENDS